Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| P1.001.001 | Adakveo | Sep 22, 2025 | Sep 20, 2026 | Adakveo® is an iv p-selectin inhibitor approved by the fda for reducing vaso-occlusive crises (voc) in... | Ver |
| P1.001.004 | Danyelza | Sep 22, 2025 | Sep 20, 2026 | Danyelza (naxitamab-gqgk) is a gd2-binding monoclonal antibody indicated, in combination with... | Ver |
| P1.001.005 | Jemperli | Sep 22, 2025 | Sep 20, 2026 | Jemperli is a programmed death receptor-1 (pd-1)–blocking antibody indicated for: endometrial cancer... | Ver |
| P1.001.006 | Margenza | Sep 22, 2025 | Sep 20, 2026 | Margenza (margetuximab-cmkb) is a her2/neu receptor antagonist indicated, in combination with chemotherapy,... | Ver |
| P1.001.007 | Monjuvi | Sep 22, 2025 | Sep 20, 2026 | Monjuvi (tafasitamab-cxix) is a cd19-directed cytolytic antibody indicated, in combination with lenalidomide,... | Ver |
| P1.001.008 | Rybrevant | Sep 22, 2025 | Sep 20, 2025 | Rybrevant (amivantamab-vmjw) is a bispecific egf receptor-directed and met receptor-directed antibody... | Ver |
| P1.001.009 | Elahere (mirvetuximab soravtansine-gynx) | Sep 22, 2025 | Sep 20, 2026 | Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (frα)-directed antibody–drug... | Ver |
| P1.001.010 | Ublituximab-xiiy (Briumvi) | Sep 22, 2025 | Sep 20, 2026 | Briumvi (ublituximab-xiiy) is a cd20-directed monoclonal antibody indicated for the treatment of adults with... | Ver |
| P1.001.011 | Imjudo (tremelimumab-actl) injection | Sep 22, 2025 | Sep 20, 2026 | Imjudo (tremelimumab-actl) is a cytotoxic t-lymphocyte–associated antigen 4 (ctla-4) blocking antibody... | Ver |
| P1.001.012 | Teclistamab (Tecvayli) | Sep 22, 2025 | Sep 20, 2026 | Teclistamab (tecvayli) is a bispecific b-cell maturation antigen (bcma)-directed cd3 t-cell engaging antibody... | Ver |
| P1.001.013 | Enjaymo | Sep 22, 2025 | Sep 20, 2026 | Sutimlimab-jome (enjaymo) is a monoclonal antibody that inhibits the classical complement pathway by binding... | Ver |
| P1.001.014 | Opdualag | Sep 22, 2025 | Sep 20, 2026 | Opdualag (nivolumab + relatlimab-rmbw) is a fixed-dose combination of two immune checkpoint inhibitors:... | Ver |
| P1.001.015 | Xenpozyme | Sep 22, 2025 | Sep 20, 2026 | Xenpozyme® (olipudase alfa-rpcp) is an enzyme replacement therapy (ert) for the treatment of non-cns... | Ver |
| P1.001.016 | Fyarro | Sep 22, 2025 | Sep 20, 2026 | Fyarro™ (nab-sirolimus) is an mtor inhibitor formulated as sirolimus protein-bound particles... | Ver |
| P1.002.001 | Vedolizumab | Dec 16, 2025 | Dec 20, 2026 | Vedolizumab is a recombinant human igg1 monoclonal antibody produced in chinese hamster ovaries. it binds to... | Ver |
| P1.002.002 | Benralizumab | Dec 16, 2025 | Dec 20, 2026 | Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
| P1.002.003 | Somatuline® Depot; Lanreotide | Dec 16, 2025 | Dec 20, 2026 | Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... | Ver |
| P1.002.004 | Nucala® (mepolizumab) | Dec 16, 2025 | Dec 20, 2026 | Nucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance treatment of... | Ver |
| P1.002.005 | Ocrevus™ (ocrelizumab) | Dec 19, 2025 | Dec 20, 2026 | Ocrelizumab is a humanized monoclonal antibody that is directed against cd20-expressing b-cells. cd20 is a... | Ver |
| P1.002.006 | Simponi ARIA® (golimumab) | Dec 19, 2025 | Dec 20, 2026 | Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... | Ver |
